AR036735A1 - Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina - Google Patents

Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina

Info

Publication number
AR036735A1
AR036735A1 ARP020103750A ARP020103750A AR036735A1 AR 036735 A1 AR036735 A1 AR 036735A1 AR P020103750 A ARP020103750 A AR P020103750A AR P020103750 A ARP020103750 A AR P020103750A AR 036735 A1 AR036735 A1 AR 036735A1
Authority
AR
Argentina
Prior art keywords
substituted
metoxi
aril
triazolo
pyridine
Prior art date
Application number
ARP020103750A
Other languages
English (en)
Inventor
Matthias Heinrich Nettekoven
Sebastien Schmitt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR036735A1 publication Critical patent/AR036735A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Compuestos de fórmula (1) en la cual: R1 es hidrógeno, halógeno o alcoxi inferior; R2 es hidrógeno, o es -C(O)-alquilo inferior ó -C(O)-fenilo, donde el anillo fenilo no está sustituido o está sustituido por uno o dos sustituyentes, seleccionados entre el grupo que comprende halógeno, alquilo inferior, alcoxi inferior o trifluormetilo, o es -C(O)-furanilo ó -C(O)-tiofenilo, donde los anillos no están sustituidos o están sustituidos por halógeno; y a sus sales farmacéuticamente aceptables. Los compuestos pueden utilizarse en el tratamiento de enfermedades relacionadas con el receptor A2 de adenosina. Y asimismo se provee el procedimiento de preparación del compuesto de fórmula (1).
ARP020103750A 2001-10-08 2002-10-04 Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina AR036735A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01123949 2001-10-08

Publications (1)

Publication Number Publication Date
AR036735A1 true AR036735A1 (es) 2004-09-29

Family

ID=8178877

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103750A AR036735A1 (es) 2001-10-08 2002-10-04 Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina

Country Status (16)

Country Link
US (1) US6693116B2 (es)
EP (1) EP1436292B1 (es)
JP (1) JP4101756B2 (es)
KR (1) KR100604407B1 (es)
CN (1) CN1254475C (es)
AR (1) AR036735A1 (es)
AT (1) ATE338043T1 (es)
AU (1) AU2002338827B2 (es)
BR (1) BR0213177A (es)
CA (1) CA2462801A1 (es)
DE (1) DE60214408T2 (es)
ES (1) ES2269772T3 (es)
MX (1) MXPA04003278A (es)
PL (1) PL370565A1 (es)
RU (1) RU2298009C2 (es)
WO (1) WO2003031445A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1830978B (zh) * 2005-03-07 2010-06-16 中国人民解放军军事医学科学院毒物药物研究所 吡唑并[4,3-c]喹啉-3-酮化合物、其制备方法及其应用
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN102131390A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
EP2288260A4 (en) * 2008-06-20 2013-10-23 Genentech Inc TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
JP5743901B2 (ja) * 2008-12-19 2015-07-01 レオ ファーマ アクティーゼルスカブ 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体
US8501936B2 (en) 2009-06-05 2013-08-06 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
EP2872509B1 (en) * 2012-07-12 2016-09-14 Chiesi Farmaceutici S.p.A. Inhibition of enzymes
NZ705677A (en) * 2012-09-14 2018-01-26 Dow Agrosciences Llc An improved process for the preparation of 2-amino-5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidine from 4-amino-2,5-dimethoxypyrimidine
MA38884A1 (fr) 2013-09-05 2017-06-30 Hoffmann La Roche Composé de triazolopyridine, compositions et procédés d'utilisation associés

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE287262C (es) *
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives

Also Published As

Publication number Publication date
ES2269772T3 (es) 2007-04-01
JP4101756B2 (ja) 2008-06-18
CN1254475C (zh) 2006-05-03
DE60214408D1 (de) 2006-10-12
US20030134873A1 (en) 2003-07-17
RU2298009C2 (ru) 2007-04-27
ATE338043T1 (de) 2006-09-15
EP1436292B1 (en) 2006-08-30
KR20040044196A (ko) 2004-05-27
CA2462801A1 (en) 2003-04-17
US6693116B2 (en) 2004-02-17
DE60214408T2 (de) 2007-03-08
KR100604407B1 (ko) 2006-07-25
MXPA04003278A (es) 2004-07-23
AU2002338827B2 (en) 2007-09-06
RU2004114277A (ru) 2006-01-10
CN1564821A (zh) 2005-01-12
JP2005508954A (ja) 2005-04-07
BR0213177A (pt) 2004-09-14
EP1436292A1 (en) 2004-07-14
WO2003031445A1 (en) 2003-04-17
PL370565A1 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
AR038419A1 (es) Derivados de piridina y quinolina
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
AR006906A1 (es) Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
PE20060504A1 (es) Derivados de pirimidina en el tratamiento de cancer
AR050281A1 (es) Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
DK1533292T3 (da) Dibenzylaminforbindelse og medicinsk anvendelse deraf
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
PE20040937A1 (es) Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4)
HUP0402107A2 (hu) N-helyettesített pirrolidinszármazékok, mint dipeptidil-peptidáz IV inhibítorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AR036057A1 (es) Compuestos derivados 4-piperazinil indol, su uso, un proceso para prepararlos y composiciones farmaceuticas que los comprenden
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR037288A1 (es) Compuestos derivados de sulfonamidas, procedimiento para la obtencion, composicion farmaceutica y uso para la elaboracion de un medicamento
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
AR040489A1 (es) Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen
PE20090960A1 (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
AR042002A1 (es) Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central.
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
AR047958A1 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.
AR008614A1 (es) UN PROCEDIMIENTO PARA LA FABRICACIoN DE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN COMPUESTO DE PIRIMIDINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DELMISMO, QUE TIENE ACTIVIDAD INHIBITORIA DE LA TIROSINA QUINASA, COMPUESTOS DE PIRIMIDINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y UN PROCEDIMI

Legal Events

Date Code Title Description
FB Suspension of granting procedure